Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Increases By 9.3%

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 107,900 shares, an increase of 9.3% from the May 31st total of 98,700 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 52,600 shares, the short-interest ratio is presently 2.1 days.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ:ABVX opened at $13.07 on Thursday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.08 and a current ratio of 4.08. The stock’s fifty day simple moving average is $13.96 and its two-hundred day simple moving average is $13.37. ABIVAX Société Anonyme has a 1-year low of $7.99 and a 1-year high of $17.02.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. BTIG Research started coverage on ABIVAX Société Anonyme in a research note on Monday, May 20th. They issued a “buy” rating and a $43.00 price objective for the company. Guggenheim started coverage on shares of ABIVAX Société Anonyme in a research report on Monday, April 29th. They issued a “buy” rating and a $50.00 price target for the company. Morgan Stanley upped their price objective on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a report on Thursday, April 11th. Finally, Piper Sandler began coverage on shares of ABIVAX Société Anonyme in a report on Monday, April 29th. They set an “overweight” rating and a $42.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $34.20.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ABVX. BNP Paribas Financial Markets purchased a new stake in shares of ABIVAX Société Anonyme during the 1st quarter valued at $81,000. Capstone Investment Advisors LLC bought a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at approximately $618,000. Ghisallo Capital Management LLC purchased a new stake in shares of ABIVAX Société Anonyme during the 4th quarter valued at approximately $642,000. Kennedy Capital Management LLC boosted its holdings in ABIVAX Société Anonyme by 35.3% in the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after buying an additional 31,331 shares during the period. Finally, Rosalind Advisors Inc. purchased a new position in ABIVAX Société Anonyme in the 1st quarter valued at approximately $5,411,000. 47.91% of the stock is owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.